Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in Minnesota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 18 | 913 | 49% |
| 2020 | 12 | 739 | 52% |
| 2021 | 13 | 771 | 56% |
| 2022 | 12 | 718 | 59% |
| 2023 | 10 | 667 | 62% |
| 2024 | 9 | 723 | 64% |
| 2025 from claims | – | 676 547–794 | 65% |
| 2026 forecast | – | 756 593–950 | 61% |
| 2027 forecast | – | 775 575–1,025 | 61% |
| 2028 forecast | – | 795 563–1,097 | 61% |
| 2029 forecast | – | 815 554–1,168 | 60% |
| 2030 forecast | – | 835 547–1,239 | 60% |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Minnesota; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 86% inpatient hospital, 14% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Ohio | 25 | 1,738−4.6%/yr | −4.6%/yr | 1.5 | 5% | 1,920 in 2030+1.7%/yr |
| Illinois | 28 | 1,515−7.1%/yr | −7.1%/yr | 1.1 | 2% | 1,670 in 2030+1.6%/yr |
| Michigan | 24 | 1,338−6.2%/yr | −6.2%/yr | 1.5 | 3% | 1,110 in 2030−3%/yr |
| Missouri | 25 | 1,166−5.8%/yr | −5.8%/yr | 1.8 | 1% | 1,250 in 2030+1.1%/yr |
| Indiana | 21 | 997−4.8%/yr | −4.8%/yr | 1.4 | 3% | 960 in 2030−0.6%/yr |
| Kansas | 11 | 616−1.8%/yr | −1.8%/yr | 1.5 | 0% | 710 in 2030+2.5%/yr |
| Wisconsin | 3 | 479−5.3%/yr | −5.3%/yr | 0.8 | 4% | 730 in 2030+7.3%/yr |
| Iowa | 9 | 408+2.6%/yr | +2.6%/yr | 0.9 | 3% | 500 in 2030+3.4%/yr |
| Nebraska | 8 | 406−2.1%/yr | −2.1%/yr | 1.5 | 6% | 480 in 2030+2.7%/yr |
| South Dakota | 4 | 201−1.4%/yr | −1.4%/yr | 1.5 | 0% | 270 in 2030+4.8%/yr |
| North Dakota | 3 | 152−5.1%/yr | −5.1%/yr | 1.5 | 0% | 160 in 2030+0.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Decompression & minimally invasive spine | 40 | 1,579−8.6%/yr | −8.6%/yr | 3.31.1× | 9% | 1,920 in 2030+3.3%/yr |
| Lumbar fusion | 38 | 1,451−4.5%/yr | −4.5%/yr | 3.11.1× | 2% | 1,850 in 2030+4.1%/yr |
| Kyphoplasty & vertebroplasty | 1 | 310−5.8%/yr | −5.8%/yr | 0.70.5× | 8% | 290 in 2030−1.1%/yr |
| SI joint fusion | 3 | 178+21%/yr | +21%/yr | 0.31.8× | 41% | 350 in 2030+12%/yr |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in Minnesota · Every state · Compare with Ohio
Medtronic leads with 66% of company spending on these surgeons in 2025, −6 pts on 2024.
In 2025, 13 companies reported engagement with Minnesota’s surgeons worth $187K in consulting, speaking, meals and travel tied to these products, about $21K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.